Skip to main content

Table 2 Net reclassification improvement of prediction models

From: Prediction models of colorectal cancer prognosis incorporating perioperative longitudinal serum tumor markers: a retrospective longitudinal cohort study

Preoperative CEA&CA19-9&CA125 model vs preoperative CEA model

 

Percentage of individuals for whom the preoperative CEA&CA19-9&CA125 model estimates a higher risk than the preoperative CEA model

Percentage of individuals for whom the preoperative CEA&CA19-9&CA125 model estimates a lower risk than the preoperative CEA model

Overall net reclassification improvement (95% confidence interval)

P for net reclassification improvement

 24 months

  Events

64.29%

35.71%

34.05% (3.29%, 64.81%)

0.015

  Non-events

47.26%

52.74%

 36 months

  Events

59.57%

40.43%

33.53% (12.28%, 54.78%)

0.001

  Non-events

42.81%

57.19%

 48 months

  Events

60.47%

39.53%

36.04% (17.18%, 54.90%)

< 0.001

  Non-events

42.45%

57.55%

 60 months

  Events

57.62%

42.38%

21.47% (2.95%, 39.99%)

0.012

  Non-events

46.88%

53.12%

Longitudinal CEA&CA19-9&CA125 model vs preoperative CEA&CA19-9&CA125 model

 

Percentage of individuals for whom the longitudinal CEA&CA19-9&CA125 model estimates a higher risk than the preoperative CEA&CA19-9&CA125 model

Percentage of individuals for whom the longitudinal CEA&CA19-9&CA125 model estimates a lower risk than the preoperative CEA&CA19-9&CA125 model

Overall net reclassification improvement (95% confidence interval)

P for net reclassification improvement

 24 months

  Events

73.81%

26.19%

64.87% (34.11%, 95.63%)

< 0.001

  Non-events

41.37%

58.63%

 36 months

  Events

62.77%

37.23%

40.81% (19.56%, 62.06%)

< 0.001

  Non-events

42.36%

57.64%

 48 months

  Events

60.47%

39.53%

30.30% (11.44%, 49.16%)

0.001

  Non-events

45.32%

54.68%

 60 months

  Events

56.95%

43.05%

24.76% (6.24%, 43.28%)

0.004

  Non-events

44.57%

55.43%

  1. Preoperative CEA model included age and sex, primary site, surgical approach, tumor differentiation, histological type, pathology stage, lymph node yield, adjuvant chemotherapy, mucinous (colloid) type, lymphovascular invasion and perineural invasion, and preoperative CEA for prediction. Preoperative CEA&CA19-9&CA125 model included age and sex, primary site, surgical approach, tumor differentiation, histological type, pathology stage, lymph node yield, adjuvant chemotherapy, mucinous (colloid) type, lymphovascular invasion and perineural invasion, and preoperative CEA for prediction. Longitudinal CEA&CA19-9&CA125 model further included preoperative CA19-9 and CA125 in addition to variables in preoperative CEA&CA19-9&CA125 model